Qrons Inc., of Miami, Fla., said it reached a milestone with the development of its two candidate products, QS-100, for treating penetrating brain injuries, and QS-200, for treating concussions and other diffused axonal injuries. Both products integrate modified mesenchymal stem cells and smart synthetic material.